<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        288-186-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SOJOURN 100% VAPOUR LIQUID FOR INHALATION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SEVOFLURANE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Inhalation vapour, liquid
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Inhaler
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        318.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PIRAMAL CRITICAL CARE INC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PIRAMAL CRITICAL CARE INC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N01AB08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient in <strong>Sojourn&reg; </strong>is sevoflurane, which is a general anaesthetic used for surgical operations and other procedures.</p><p>It is an inhaled anaesthetic that is given to you as a vapour for you to breathe in.</p><p>It causes you to fall into a deep sleep (induction of anaesthesia). It also maintains a deep, painless sleep during which you can undergo surgery (maintenance of anaesthesia). You must talk to a doctor if you do not feel better or if you feel worse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Sojourn&reg; </strong>should be administered only by healthcare professionals appropriately trained in the administration of general anaesthesia under the supervision of or by an anaesthetist.</p><p><strong>You should not be given Sojourn&reg;, if any of the following applies to you, please tell your doctor if:</strong></p><p>- There are medical reasons why you should not be given a general anaesthetic.</p><p>- You have been told previously that you should not receive general anaesthesia.</p><p>- You are hypersensitive (or allergy) to sevoflurane or other similar anaesthetic.</p><p>- You, or anyone in your family, are susceptible to a condition called malignant hyperthermia (rapid rise in body temperature and severe muscle contractions) during anaesthesia.</p><p>- You have liver problems or if you have previously had general anaesthetics, particularly if repeated over a short period of time. Some anaesthetics can occasionally cause problems in the liver, which can cause yellowing of the skin and eyes (jaundice).</p><p>- You have ever had QT prolongation (prolongation of a specific time interval in an ECG) or torsade de pointes (a specific type of heart rhythm), which may also be associated with QT prolongation. Sevoflurane has sometimes been known to cause these.</p><p>- You are prone to or at risk for seizures (fits).</p><p>- You have a mitochondrial disease.</p><p><strong>Warnings and precautions </strong></p><p><strong>Talk to your doctor before taking </strong><strong>Sojourn&reg; </strong><strong>if: </strong></p><p>- You have previously had general anaesthetics, particularly if repeated over a short period of time. You may have an increased risk of liver problems.</p><p>- You are suffering from any illness, other than those connected with your operation, particularly any kidney or heart problems, low blood pressure, severe headaches, nausea or vomiting or Pompe&#39;s disease in children (a metabolic disorder). Sevoflurane may produce abnormal heart rhythms, which may be severe in some cases.</p><p>- You have a certain type of muscle weakness (myasthenia gravis) because people with this disease are very sensitive to medicinal products that suppress breathing.</p><p>- You have a coronary artery disease.</p><p>- You are hypovolaemic (reduced blood volume) or weak.</p><p>- You suffer from a neuromuscular disease, particularly Duchenne muscular dystrophy.</p><p>- You have raised pressure in the skull (intracranial pressure), such as from a head injury or brain tumour.</p><p>- You have seizures or seizure disorders (fits), as sevoflurane may increase the risk of seizures.</p><p>- You are pregnant or breastfeeding.</p><p><strong>Children </strong></p><p>&bull;&nbsp;&nbsp; You have Down syndrome</p><p>In children with Down Syndrome who receive sevoflurane, a severe slowing of the heart rate and cardiac arrest which is not related to underlying congenital heart disease can occur.</p><p>If any of the above apply to you check with your doctor, nurse or pharmacist. You may need to be checked carefully and your treatment may be changed.</p><p><strong>The following effects may occur during or after </strong><strong>Sojourn&reg; </strong><strong>administration: </strong></p><p>During the period in which you are anesthetized (induction phase), sevoflurane, as well as medicinal products that resemble it&nbsp;(halogenated anesthetics), may induce coughing. This must be taken into account.</p><p>- As with other anesthetics, minor mood changes may occur for a number of days after sevoflurane administration. &nbsp;</p><p>- Young children under the age of six are more likely to experience acute confusion (delirium) when waking up from anesthesia. In addition, children under the age of six are more likely to experience agitation/anxiety when waking up from anesthesia.</p><p>- In sensitive patients, anesthetics given by inhalation (inhalation anesthetics) may cause an increased metabolic (hypermetabolic) state of the skeletal muscles. This leads to high oxygen requirements of your muscles due to too high levels of CO2 in the blood (hypercapnia). In that case you may experience muscle stiffness (muscle rigidity), increased heart rate (tachycardia), increased breathing (tachypnea), blue discoloration of the lips, tongue, skin, and mucous membranes (cyanosis), heart rhythm disturbances (arrhythmia), and/or unstable blood pressure.</p><p>- In rare cases, the use of inhaled anesthetics (inhaled anesthetics) has been associated with an increased potassium level in the blood fluid (increase in serum potassium levels) that have led to heart rhythm disturbances (arrhythmias) and death in children after surgery.</p><p>- Sevoflurane may cause respiratory depression, which may be increased by narcotic premedication or other medicinal products that cause respiratory depression. Respiration should be monitored and if necessary be supported.</p><p><strong>Other medicines and </strong><strong>Sojourn&reg;</strong></p><p>Tell your doctor if you are taking or have recently taken any of the following:</p><p>The medicines or active substances contained in the medicines listed below may influence each other&#39;s effect when used together with Sevoflurane. Some of these medicines are given to you during your surgery by your anaesthetist, as indicated in the description.</p><p>- Amphetamines (stimulants): used to treat attention-deficit hyperactivity disorder (ADHD) or narcolepsy</p><p>- Medicines that affect the heart such as adrenaline or epinephrine</p><p>- Beta blockers (e.g., atenolol, propranolol): These are heart medicines often given to treat a high blood pressure.</p><p>- Alcohol</p><p>- Barbiturates (depressant)</p><p>- St. John&#39;s Wort (an herbal remedy used to help with depression)</p><p>- Decongestants (ephedrine): used as a decongestant and commonly found in cough and cold medicines.</p><p>- Non-selective monoamine oxidase (MAO) inhibitors (a type of antidepressants)</p><p>- Calcium antagonists</p><p>- Verapamil: This is a heart medicine, and it is given to treat a high blood pressure or when you suffer from an irregular heart beat.</p><p>- Tranquillisers (benzodiazepines e.g., diazepam, lorazepam): These are sedative medicines, which have a calming effect. They are used when you feel nervous for instance before your surgery.</p><p>- Strong painkillers such as morphine or codeine</p><p>- Muscle relaxants (Non-depolarising e.g., vecuronium, pancuronium, atracurium and depolarising e.g. succinylcholine): These medicines are used during general anaesthesia to relax your muscles.</p><p>- Isoniazid, used to treat tuberculosis (TB)</p><p>- Isoprenaline</p><p>&bull; Other anaesthetics, e.g. nitrous oxide: This is a medicine used during general anaesthesia that will cause you to sleep and will ease your pain, propofol, opioids (e.g. alfentanil and sufentanil): These medicines are strong pain killers and are often used during general anaesthesia as sevoflurane may affect the way they work if they are given at the same time.</p><p>Please tell your doctor or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. This also applies to herbal medicinal products, vitamins and minerals.</p><p><strong>Sojourn&reg; </strong><strong>with food and drink </strong></p><p><strong>Sojourn&reg; </strong>is a medicine to make and keep you asleep so you can undergo surgery. You should ask your doctor, surgeon or anaesthetist when and what you can eat or drink after you wake up.</p><p><strong>Pregnancy and breast feeding </strong></p><p>Tell your doctor or anaesthetist if you are pregnant or think you may be pregnant or are breast feeding. It is not known whether sevoflurane or its by-products are transferred into human milk. It is advisable to stop breast-feeding for 48 hours after sevoflurane administration and discard any milk that is produced during this period. You should not receive <strong>Sojourn&reg; </strong>if you are pregnant unless it is essential.</p><p>The use of sevoflurane for anesthesia during a C-section is safe for you as well as for your baby. The safety of sevoflurane during contractions and natural birth has not been demonstrated. Like other anesthetics, sevoflurane may cause reduced respiration in neonates. Your doctor will determine whether you may use sevoflurane.</p><p><strong>Driving and using machines </strong></p><p><strong>Sojourn&reg; </strong>severely influences your ability to drive and operate tools. Do not drive or operate tools or machines until your doctor tells you it is safe. Receiving an anaesthetic may influence your alertness for several days. This may affect your ability to carry out tasks that require mental alertness.</p><p>Ask your anaesthetist when it will be safe for you to drive and use machines again.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Sojourn&reg; </strong>will be given by a trained anaesthetist in a surgery or hospital. The anaesthetist will decide how much sevoflurane you need and when it is to be given. The dose will vary according to your age, weight, the type of surgery you need, and other medicines given to you during surgery.</p><p><strong>Sojourn&reg; </strong>is changed to vapour (gas) in a vaporiser. You will breathe it in as a vapour.</p><p>It may be used to put you to sleep before your operation or, if you are put to sleep with an injection, it may be used to maintain anaesthesia during the operation.</p><p>Once the anaesthetist stops you from inhaling sevoflurane, you will wake up within a few minutes.</p><p>If you have any further questions on the use of this product, ask your anaesthetist, doctor or nurse.</p><p><strong>If you receive more </strong><strong>Sojourn&reg; </strong><strong>than you should </strong></p><p><strong>Sojourn&reg; </strong>will be given to you by a healthcare professional and it is not likely that you will receive too much <strong>Sojourn&reg;</strong>. If you are given too much <strong>Sojourn&reg;</strong>, your anaesthetist will take any necessary measures.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Sojourn&reg; </strong>&nbsp;can cause side effects, although not everybody gets them. It is however, important to consult your ward doctor, nurse or anaesthetist if you are feeling unwell.</p><p><strong>Serious rare side effects </strong>(can be life-threatening)<strong>: </strong></p><p>- Anaphylaxis and anaphylactoid reactions (see not known side effects section for more information).</p><p>The following side effects are serious and you may need immediate medical attention. Hospital staff will monitor you throughout your anaesthesia and will give immediate assistance when necessary.</p><p><strong>Tell the doctor or nurse immediately if you have any of the following: </strong></p><p>- Allergic reactions, which can be severe, with swelling of the face, tongue and throat and difficulty breathing.</p><p>- Malignant hyperthermia (very high temperature), which may require intensive care and may be fatal. This condition may run in families.</p><p>- Increased potassium levels in the blood (hyperkalaemia), which may result in abnormal heart rhythms and can be fatal in children during the post-operative phase. This has been seen in patients with neuromuscular disease, particularly Duchenne muscular dystrophy.</p><p><strong>If you experience any of the following, tell your doctor or nurse: </strong></p><p><strong>Very common side effects (may affect more than 1 in 10 people) </strong></p><p>- restlessness (agitation) in children</p><p>- slow heart rate (bradycardia)</p><p>- low blood pressure</p><p>- coughing</p><p>- nausea and vomiting.</p><p><strong>Common side effects (may affect up to 1 in 10 people) </strong></p><p>- headache</p><p>- drowsiness</p><p>- dizziness</p><p>- fast heart rate</p><p>- increased blood pressure</p><p>- breathing disorder</p><p>- airway obstruction</p><p>- slow and shallow breathing</p><p>- throat spasm, respiratory problems</p><p>- mouth watering</p><p>- hypothermia, chills</p><p>- fever</p><p>- abnormal blood sugar level, liver function test or white blood cell counts i.e. increased susceptibility to infections</p><p>- increased blood fluoride.</p><p><strong>Uncommon side effects (may affect up to 1 to 100 people) </strong></p><p>- confusion</p><p>- abnormal heart rhythm and abnormal heart beats</p><p>- AV blockade (a disorder of the electrical conduction of the heart)</p><p>- stopping breathing, low oxygen levels, fluid on the lungs</p><p>- retention of urine, glucose in the urine</p><p>- increased blood creatinine levels (an indicator of poor kidney function), as detected by a blood sample test.</p><p><strong>Other side effects [frequency not known (frequency cannot be estimated from available data)] </strong></p><p>- asthma</p><p>- allergic reactions e.g.:</p><p>- rash</p><p>- redness of the skin</p><p>- urticaria (hives)</p><p>- itching</p><p>- swollen eyelids, breathing difficulties</p><p>- anaphylaxis and anaphylactoid reactions. These allergic reactions occur quickly and can be life-threatening. Symptoms of anaphylaxis include:</p><p>- malignant hyperthermia</p><p>- angioedema (swelling of the skin of the face, limbs, lips, tongue or throat)</p><p>- breathing difficulties</p><p>- low blood pressure</p><p>- urticaria (hives)</p><p>- epilepsy-like fits</p><p>- sudden twitching movements</p><p>- cardiac arrest</p><p>- cramping of the airways</p><p>- difficulty in breathing or wheezing</p><p>- breath holding</p><p>- shortness of breath</p><p>- reduced liver function or hepatitis (inflamed liver), characterised by e.g. loss of appetite, fever, nausea, vomiting, abdominal discomfort, jaundice and dark urine.</p><p>- dangerously raised body temperature</p><p>- chest discomfort</p><p>- a rise in the pressure inside the skull</p><p>- irregular heart beat or palpitations</p><p>- inflammation of the pancreas</p><p>- Increases in blood potassium levels as detected by a blood sample test</p><p>- muscle stiffness</p><p>- inflammation of the kidneys (symptoms may include fever, confusion or sleepiness, rash, swelling, more or less urine than normal, and blood in the urine)</p><p>- swelling</p><p>Sometimes seizures (fits) are seen. These can occur when receiving Sevoflurane or up to a day later during recovery. They occur mostly in children and young adults.</p><p>In children with Down Syndrome who receive sevoflurane, a slowing of the heart rate can occur. Children with Pompe&#39;s disease, a disease that they are born with, may have irregular heart rhythm during anaesthesia with sevoflurane.</p><p>Levels of fluoride in the blood may be raised slightly during and immediately after anaesthesia, but these levels are not thought to be harmful and soon return to normal.</p><p>If any of the side effects get serious, or if you notice any side effects not listed in the leaflet, please tell your doctor or pharmacist.</p><p>If you notice any change in the way you feel after receiving sevoflurane, please inform your doctor or pharmacist. Some side effects may need treatment.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Reporting of side effects </u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p><strong>&bull; Saudi Arabia:</strong></p><p><strong>&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p>-&nbsp;&nbsp; <strong>Fax</strong><strong>: </strong>+966-11-205-7662</p><p>-&nbsp;&nbsp; <strong>SFDA Call Centre:</strong> 19999</p><p>-&nbsp;&nbsp; <strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp; <strong>Website: </strong>https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States:</strong></p><p>-&nbsp;&nbsp; Please contact the relevant competent authority</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.</p><p>- Do not use <strong>Sojourn&reg; </strong>after the expiry date which is stated on both the bottle label and carton. The expiry date refers to the last day of that month.</p><p>- Do not store above 30&deg;C. Do not refrigerate. Keep cap tightly closed.</p><p>- Do not take <strong>Sojourn&reg; </strong>if you notice any visible sign of deterioration.</p><p>- Medicines should<em> </em>not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Sojourn&reg; </strong>contains 100% of the active ingredient sevoflurane. There are no other ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sojourn® Volatile liquid for inhalation are available in amber-colored bottles containing 250 mL.  
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured By: <strong>Piramal Critical Care, Inc.</strong></p><p>3950 Schelden Circle, Bethlehem, PA 18017, USA.</p><p>(888) 822-8431</p><p>Marketed by: Julphar, Gulf Pharmaceutical Industries</p><p>Ras Al Khaimah, U.A.E.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/04/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:91.05pt;margin-top:.75pt;width:21.2pt;
 height:5.75pt;z-index:251649024'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" />يحتوي <strong>سوجورن</strong> على مادة دوائية تعرف باسم سيفوفلوران. حيث يستعمل في التخدير العام في العمليات الجراحية و في العمليات الطبية الأخرى.</p><p dir="RTL">وهو عبارة عن بخاخ مخدر يعطى لك على هيئة بخار للاستنشاق، حيث يعمل على إدخالك في نوم عميق (عملية تحريض التخدير). بالإضافة إلى أنه يعمل على الحفاظ على النوم العميق دون الشعور بأية آلام وذلك للتمكن من الخضوع للعملية الجراحية (عملية الحفاظ على التخدير). يرجى منك التحدث إلى طبيبك المعالج في حال كنت لم تشعر بأي تحسن أو ساءت الأعراض لديك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:80.7pt;margin-top:.4pt;width:21.2pt;
 height:5.75pt;z-index:251650048'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" />يجب إعطاء&nbsp;<strong>سوجورن&nbsp;</strong>فقط من قبل طبيب التخدير أو ممارسي الرعاية الصحية المدربين تدريباً خاصاً في إعطاء التخدير العام وذلك تحت إشراف طبيب التخدير.</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1027"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:63.2pt;margin-top:.05pt;width:21.2pt;height:5.75pt;z-index:251651072'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" /><strong>يجب </strong><strong>عليك عدم تلقي&nbsp;سوجورن ، في حال كان أياً مما يلي ينطبق عليك، كما يرجى منك إخبار طبيبك المعالج إذا: </strong></p><p dir="RTL">-&nbsp;&nbsp; كانت لديك أسباب طبية تتمثل في عدم إعطائك أدوية التخدير العام.</p><p dir="RTL">-&nbsp;&nbsp; كان قد تم إخبارك مسبقاً بعدم استخدام أياً من أدوية التخدير العام.</p><p dir="RTL">-&nbsp;&nbsp; كنت تعاني من فرط الحساسية (أو حساسية) تجاه سيفوفلوران أو أي أدوية تخدير أخرى مماثلة.</p><p dir="RTL">-&nbsp;&nbsp; كنت عرضة أو أي &nbsp;أحد من أفراد عائلتك للإصابة بحالة تعرف باسم فرط الحرارة الخبيث (ارتفاع سريع في درجة حرارة الجسم وتقلصات عضلية شديدة) أثناء التخدير.</p><p dir="RTL">-&nbsp;&nbsp; كنت تعاني من مشاكل في الكبد أو كنت قد خضعت مسبقاً للتخدير العام، وبصفة خاصة في حال تم تكرار ذلك خلال فترة زمنية قصيرة. من الممكن أحياناً أن تسبب بعض أدوية التخدير مشاكل في الكبد، والتي قد تسبب اصفرار في الجلد والعينين (اليرقان).</p><p dir="RTL">-&nbsp;&nbsp; كنت قد عانيت في أي وقت مضى من إطالة فترة كيو تي (إطالة فترة زمنية محددة في تخطيط كهربائية القلب) أو تورساد دي بوينت (نوع معين من ضربات القلب) والذي قد يرتبط أيضًا بإطالة فترة كيو تي. حيث أنه من المعروف أن سيفوفلوران قد يسبب ذلك أحيانًا.</p><p dir="RTL">-&nbsp;&nbsp; كنت عرضة لخطر حدوث الصرع (نوبات)</p><p dir="RTL">-&nbsp;&nbsp; كنت تعاني من مرض الميتوكندريا.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1028" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:8.05pt;
 margin-top:.45pt;width:21.2pt;height:5.75pt;z-index:251652096'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" /><strong>يرجى منك التحدث مع طبيبك المعالج قبل استعمال سوجورن في الحالات التالية: </strong></p><p dir="RTL">-&nbsp;&nbsp; كنت قد خضعت مسبقاً لإجراء تخدير عام، وبصفة خاصة إذا تم تكرار ذلك خلال فترة زمنية قصيرة. &nbsp;كما قد يزداد خطر حدوث مشاكل في الكبد.</p><p dir="RTL">-&nbsp;&nbsp; كنت تعاني من أية أمراض غير متعلقة بالعملية الجراحية، وخاصة أية مشاكل في الكلى أو القلب، انخفاض ضغط الدم، صداع شديد، غثيان أو تقيؤ أو مرض بومبي لدى الأطفال (اضطراب استقلابي). قد يؤدي سيفوفلوران إلى حدوث اضطرابات في ضربات القلب والتي قد تكون شديدة في بعض الحالات.</p><p dir="RTL">-&nbsp;&nbsp; كنت تعاني من نوع معين من ضعف في العضلات (الوهن العضلي الوبيل)، وذلك لأن الأشخاص المصابين بهذا المرض حساسون جدًا تجاه الأدوية التي تثبط التنفس.</p><p dir="RTL">-&nbsp;&nbsp; كنت تعاني من مرض الشريان التاجي.</p><p dir="RTL">-&nbsp;&nbsp; &nbsp;كنت تعاني من نقص حجم الدم (انخفاض في حجم الدم) أو الشعور بالضعف.</p><p dir="RTL">-&nbsp;&nbsp; كنت تعاني من مرض عصبي عضلي، وبصفة خاصة الحثل العضلي الدوشيني.</p><p dir="RTL">-&nbsp;&nbsp; كنت تعاني من ارتفاع ضغط الجمجمة (الضغط داخل القحف)، على سبيل المثال إصابة في الرأس أو ورم في المخ.</p><p dir="RTL">-&nbsp;&nbsp; كنت تعاني من الصرع أو اضطرابات الصرع (نوبات)، وذلك لأن سيفوفلوران قد يزيد من خطر حدوث هذه النوبات.</p><p dir="RTL">- كنت حاملاً أو ترضعين طفلك رضاعة طبيعية.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">&bull;&nbsp; كنت تعاني من متلازمة داون</p><p dir="RTL">من الممكن أن يحدث تباطؤ شديد في معدل ضربات القلب وتوقف القلب الغير مرتبط بعيوب القلب الخلقية لدى الأطفال الذين يعانون من متلازمة داون والذين يتلقون سيفوفلوران.</p><p dir="RTL">يرجى منك استشارة طبيبك المعالج، الممرض أو الصيدلي الذي تتعامل معه في حال كان أياً مما ذكرأعلاه ينطبق عليك. قد تحتاج إلى المراقبة عن كثب كما قد يتم تغيير العلاج الخاص بك. &nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1029" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:-1.6pt;
 margin-top:.7pt;width:21.55pt;height:5.85pt;z-index:251653120'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="29" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image003.gif" /><strong>قد تحدث التأثيرات الجانبية التالية أثناء أو بعد استعمال&nbsp;سوجورن</strong></p><p dir="RTL">-&nbsp;&nbsp; يجب الأخذ في عين الاعتبار، من أنه قد يسبب دواء سيفوفلوران والأدوية المماثلة له (أدوية التخدير المهلجنة) في حدوث السعال وذلك خلال الفترة التي يتم فيها تخديرك (عملية تحريض التخدير).</p><p dir="RTL">-&nbsp;&nbsp; كما هو الحال مع أدوية التخدير الأخرى، قد تحدث تغيرات طفيفة في المزاج لعدة أيام بعد استعمال سيفوفلوران.</p><p dir="RTL">-&nbsp;&nbsp; إن الأطفال الصغار الذين تبلغ أعمارهم أقل من 6 سنوات هم أكثر عرضة للإصابة بالارتباك الحاد (الهذيان) عند الاستيقاظ من التخدير. بالإضافة إلى ذلك، من المرجح أن يعاني الأطفال الذين تبلغ أعمارهم أقل من 6 سنوات من التهيج / القلق عند الاستيقاظ من التخدير.</p><p dir="RTL">-&nbsp;&nbsp; قد تؤدي أدوية التخدير التي تُعطى عن طريق الاستنشاق (التخدير عن طريق الاستنشاق) &nbsp;لدى المرضى الذين يعانون من الحساسية إلى زيادة في التمثيل الغذائي (فرط التمثيل الغذائي) في عضلات الهيكل العظمي. يعود هذا إلى الارتفاع في متطلبات الأكسجين للعضلات إلى المستويات العالية جداً من ثاني أكسيد الكربون في الدم (فرط ثائي أكسيد الكربون). في هذه الحالة قد تعاني من تصلب العضلات، زيادة معدل ضربات القلب، زيادة التنفس، تغير لون الشفتين، اللسان، الجلد والأغشية المخاطية (تلون الجلد باللون الأزرق)، اضطرابات نظم ضربات القلب (عدم انتظام ضربات القلب) و / أو عدم استقرار ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp; في حالات نادرة، ارتبط استخدام التخدير عن طريق الاستنشاق بزيادة مستوى البوتاسيوم في سوائل الدم مما أدى إلى اضطرابات في نظم القلب (عدم انتظام ضربات القلب) والوفاة عند الأطفال بعد إجراء العملية الجراحية.</p><p dir="RTL">-&nbsp;&nbsp; قد يؤدي سيفوفلوران إلى حدوث تثبيط في الجهاز التنفسي، والذي قد يزداد عن طريق أدوية التخدير أو غيرها من المنتجات الطبية التي تتسبب في تثبيط الجهاز التنفسي. يجب مراقبة التنفس و القيام في دعم الأمر في حال لزم الأمر لذلك.</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1030"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:38.2pt;margin-top:.85pt;width:21.2pt;height:5.75pt;z-index:251654144'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" /><strong>تناول الأدوية الأخرى بالتزامن مع&nbsp;سوجورن</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج<strong> </strong>إذا كنت تتناول أو تناولت مؤخراً أياً من الأدوية التالية:</p><p dir="RTL">قد تؤثر الأدوية أو المواد الفعالة الموجودة في الأدوية المذكورة أدناه على تأثير بعضها البعض عند استخدامها بالتزامن مع سيفوفلوران . قد يتم إعطاء بعض هذه الأدوية لك أثناء العمليات الجراحية من قبل طبيب التخدير الخاص بك، &nbsp;كما هو موضح في الوصف.</p><p dir="RTL">-&nbsp;&nbsp; الأمفيتامينات (المنشطات): تستخدم لعلاج اضطراب فرط الانتباه الناجم عن الحركة أو النوم القهري</p><p dir="RTL">-&nbsp;&nbsp; الأدوية التي تؤثر على القلب مثل الأدرينالين أو الإبينفرين</p><p dir="RTL">-&nbsp;&nbsp; حاصرات بيتا (على سبيل المثال أتينولول، بروبرانولول): تعطى هذه الأدوية غالباً لعلاج ارتفاع ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp; الكحول</p><p dir="RTL">-&nbsp;&nbsp; الباربيتورات (مثبطات)</p><p dir="RTL">-&nbsp;&nbsp; عشبة ست جونز ورت (وهو علاج عشبي يستخدم للمساعدة في علاج الاكتئاب)</p><p dir="RTL">-&nbsp;&nbsp; مزيلات الاحتقان (الايفيدرين): تستخدم كمزيل للاحتقان وعادة ما توجد في أدوية السعال والبرد.</p><p dir="RTL">-&nbsp;&nbsp; مثبطات أكسیداز أحادي الأمین (يستخدم لعلاج الاكتئاب).</p><p dir="RTL">-&nbsp;&nbsp; غالقات قنوات الكالسیوم</p><p dir="RTL">-&nbsp;&nbsp; فيراباميل: وهو دواء يستخدم للقلب، حيث يعطى لعلاج ارتفاع ضغط الدم أو عند المعاناة من عدم انتظام ضربات القلب.</p><p dir="RTL">-&nbsp;&nbsp; مهدئات الأعصاب (البنزوديازيبينات على سبيل المثال ديازيبام، لورازيبام): وهي أدوية مهدئة لها تأثير مهدئ. يتم استخدامها عندما تشعر بالتوتر على سبيل المثال قبل إجراء العملية الجراحية.</p><p dir="RTL">-&nbsp;&nbsp; المسكنات القوية على سبيل المثال المورفين أو الكودايين</p><p dir="RTL">-&nbsp;&nbsp; الأدوية المرخية للعضلات (الغير مزيلة للاستقطاب على سبيل المثال: فيكورونيوم، بانكورونيوم، أتراكوريوم ومزيل للاستقطاب مثل سكسينيل كولين): تستخدم هذه الأدوية أثناء التخدير العام لإرخاء العضلات.</p><p dir="RTL">-&nbsp;&nbsp; &nbsp;أيزونيازيد ، وتستعمل لعلاج السل الرئوي.</p><p dir="RTL">-&nbsp;&nbsp; &nbsp;الآيزوبرينالين</p><p dir="RTL">&bull;&nbsp; أدوية التخدير الأخرى، على سبيل المثال أكسيد النيتروز: يستخدم هذا الدواء أثناء التخدير العام الذي يعمل على إدخالك في نوم عميق سيجعلك تنام ويخفف شعورك بالألم، البروبوفول، المواد الأفيونية (على سبيل المثال الفنتانيل والسوفنتانيل): تعد هذه الأدوية مسكنات قوية لعلاج الألم وغالباً ما تستخدم أثناء التخدير العام؛ وذلك لأن سيفوفلوران قد يؤثر على آلية عمل تلك الأدوية إذا تم إعطاؤهم في نفس الوقت.</p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الممرض إذا كنت تتناول أو تناولت مؤخراً أية أدوية أخرى، بما في ذلك الأدوية التي تصرف دون وصفة طبية. ينطبق هذا أيضاً على المنتجات الطبية العشبية، الفيتامينات والمعادن.</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1031" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:87.4pt;
 margin-top:.75pt;width:21.2pt;height:5.75pt;z-index:251655168'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" /><strong>استعمال سوجورن مع الطعام والشراب </strong></p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1032"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:94.15pt;margin-top:.65pt;width:21.2pt;height:5.75pt;z-index:251656192'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" />يعمل &nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong>&nbsp;على إدخالك في نوم عميق ويبقيك نائماً حتى تتمكن من الخضوع للعملية الجراحية. يرجى منك استشارة طبيبك المعالج أو الطبيب الجراح أو طبيب التخدير حول ما يمكنك تناوله أو شربه عند الاستيقاظ من النوم.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو طبيب التخدير إذا كنت حاملاً أو تعتقدين أنك حاملاً أو ترضعين طفلك رضاعة طبيعية.</p><p dir="RTL">من غير المعروف حول ما إذا كان سيفوفلوران أو منتجاته الثانوية يفرز في حليب الأم. يوصى بالتوقف عن الرضاعة الطبيعية لمدة 48 ساعة بعد استعمال سيفوفلوران والقيام بالتخلص من أي حليب طبيعي يتم إنتاجه خلال هذه الفترة.</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1033" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:43.45pt;
 margin-top:.7pt;width:21.2pt;height:5.75pt;z-index:251657216'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" />إذا كنت حاملاً، يجب عدم تلقي&nbsp;<strong>سوجورن&nbsp;&nbsp;</strong>إلا في حال لزم الأمر لذلك.</p><p dir="RTL">لقد تبين أن استخدام سيفوفلوران أثناء العملية القيصرية آمن لك ولطفلك. لم يتم إثبات مدى سلامة سيفوفلوران أثناء الانقباضات والولادة الطبيعية. كما هو الحال مع أدوية التخدير الأخرى، قد يتسبب سيفوفلوران في انخفاض التنفس لدى الأطفال حديثي الولادة. سوف يقوم طبيبك المعالج بتحديد ما إذا كان بإمكانك استخدام سيفوفلوران.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1034" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:94.4pt;
 margin-top:.7pt;width:21.2pt;height:5.75pt;z-index:251658240'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" />يؤثر&nbsp;&nbsp;<strong>سوجورن&nbsp;</strong>بشدة على قدرتك على القيادة واستخدام الآلات. يرجى منك عدم القيادة أو استخدام الأدوات والآلات إلا في حال كان قد أخبرك طبيبك المعالج بأمان استعماله. قد يؤثر تلقي أدوية التخدير على قدرتك على اليقظة لعدة أيام. كما قد يؤثر ذلك على قدرتك على تنفيذ المهام التي تتطلب اليقظة العقلية.</p><p dir="RTL">يرجى منك استشارة طبيب التخدير الخاص بك عن الوقت الآمن و المناسب للقيادة واستخدام الآلات مرة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:71.75pt;margin-top:.8pt;width:21.2pt;
 height:5.75pt;z-index:251660288'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" />سوف يتم إعطاء <strong>سوجورن&nbsp;</strong>من قبل طبيب التخدير المتدرب أثناء العمليات الجراحية أو في المستشفى. سوف يقرر طبيب التخدير حول الكمية اللازمة التي تحتاجها من سيفوفلوران والوقت المناسب لاستعماله.</p><p dir="RTL">يختلف مقدار الجرعة اعتماداً على عمرك، وزنك، نوع العملية الجراحية التي تحتاجها والأدوية الأخرى التي تُعطى لك أثناء العملية الجراحية.</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="_x0000_s1027" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:75.8pt;
 margin-top:.55pt;width:21.2pt;height:5.75pt;z-index:251661312'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" />سوف يتم تغيير&nbsp;<strong>سوجورن&nbsp;</strong>إلى بخار (غاز) في مبخر. يتم استنشاقه على هيئة بخار.</p><p dir="RTL">قد يتم استعماله لإدخالك في النوم قبل إجراء العملية الجراحية أو، في حال كنت قد دخلت في النوم بواسطة استخدام حقنة، فقد يستعمل للحفاظ على التخدير أثناء العملية الجراحية.</p><p dir="RTL">بمجرد أن يتوقف طبيب التخدير من إعطائك سيفوفلوران لاستنشاقه، ستستيقظ في غضون بضع دقائق.</p><p dir="RTL">يرجى منك استشارة طبيب التخدير، الطبيب المعالج أو الممرض في حال كان لديك أية أسئلة أخرى حول استعمال هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إ<strong>ذا كنت قد أعطيت &nbsp;سوجورن&nbsp;بجرعة أكبر مما يجب </strong></p><p dir="RTL">من الغير محتمل أن يتم إعطاؤك <strong>سوجورن&nbsp;</strong>بجرعة أكبر مما يجب وذلك لأنه سوف يتم إعطاؤك <strong>سوجورن&nbsp;</strong>من قبل اخصائي الرعاية الصحية.</p><p>في حال كان قد تم إعطاؤك جرعة أكبر مما يجب، فسوف يقوم طبيب التخدير الخاص بك باتخاذ الإجراءات اللازمة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يؤدي <strong>سوجورن&nbsp;</strong>إلى حدوث تأثيرات جانبية، ولكنها قد لا تحدث لكل شخص، على الرغم من ذلك، إذا كنت تشعر بالتوعك فإنه من المهم استشارة الطبيب المعالج المسؤول عن الجناح، الممرض أو طبيب التخدير.</p><p dir="RTL"><strong>تأثيرات جانبية خطيرة ونادرة </strong>(من الممكن أن تكون مهددة للحياة):</p><p dir="RTL">- الحساسية المفرطة والتفاعلات التأقية (انظر قسم التأثيرات الجانبية الغير معروفة للحصول على المزيد من المعلومات).</p><p dir="RTL">الآثار الجانبية التالية خطيرة وقد تحتاج إلى عناية طبية فورية. سوف يقوم موظفو المستشفى بمراقبتك عن كثب طوال فترة التخدير وسوف يقدمون لك المساعدة الفورية عند الضرورة.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج أو الممرض على الفور إذا كنت تعاني أياً مما يلي:</strong></p><p dir="RTL">- تفاعلات تحسسية، والتي من الممكن أن تكون شديدة، يصاحبها تورم في الوجه، اللسان، الحلق وصعوبة في التنفس.</p><p dir="RTL">- فرط الحرارة الخبيث (ارتفاع درجة الحرارة بصورة مفرطة)، والتي قد تتطلب عناية مكثفة والتي من الممكن أن تكون قاتلة. قد تنتقل هذه الحالة لدى العائلات.</p><p dir="RTL">- &nbsp;ارتفاع مستويات البوتاسيوم في الدم (فرط بوتاسيوم الدم)، مما قد يؤدي إلى عدم انتظام ضربات القلب ويمكن أن يكون قاتلاً لدى الأطفال خلال مرحلة ما بعد العملية الجراحية. وقد لوحظ هذا في المرضى الذين يعانون من مرض عصبي عضلي، وخاصة الحثل العضلي الدوشيني.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج أو الممرض في حال ملاحظة أياً من التأثيرات التالية: </strong></p><p dir="RTL"><strong>تأثيرات جانبية شائعة جداً (قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">- الشعور بعدم الارتياح (التهيج) عند الاطفال</p><p dir="RTL">- تباطؤ في معدل ضربات القلب )بطء القلب(.</p><p dir="RTL">- انخفاض ضغط الدم</p><p dir="RTL">- السعال</p><p dir="RTL">- الغثيان والتقيؤ.</p><p dir="RTL"><strong>تأثيرات جانبية شائعة (قد تؤثر مايصل إلى شخص واحد من كل 10 أشخاص) </strong></p><p dir="RTL">- صداع</p><p dir="RTL">- نعاس</p><p dir="RTL">- دوار</p><p dir="RTL">- تسارع في معدل ضربات القلب</p><p dir="RTL">- ارتفاع ضغط الدم</p><p dir="RTL">- اضطرابات في التنفس</p><p dir="RTL">- انسداد مجرى الهواء</p><p dir="RTL">- التنفس بشكل بطيء وسطحي</p><p dir="RTL">- تشنج الحلق، مشاكل في الجهاز التنفسي</p><p dir="RTL">- سيلان اللعاب</p><p dir="RTL">- انخفاض درجة حرارة الجسم، قشعريرة</p><p dir="RTL">- حمى</p><p dir="RTL">- مستويات غير طبيعية في سكر الدم، فحوصات وظائف الكبد أو تعداد خلايا الدم البيضاء مما يعني زيادة القابلية للإصابة بالعدوى</p><p dir="RTL">- زيادة مستوى الفلوريد في الدم.</p><p dir="RTL"><strong>تأثيرات جانبية غير شائعة (قد تؤثر مايصل إلى شخص واحد من كل 100 شخص)</strong></p><p dir="RTL">- ارتباك</p><p dir="RTL">- عدم انتظام نظم ضربات القلب وعدم انتظام ضربات القلب</p><p dir="RTL">- الإحصار الأذيني البطيني (اضطراب في التوصيل الكهربائي للقلب)</p><p dir="RTL">- توقف التنفس، انخفاض مستويات الأكسجين، تكون سوائل على الرئتين</p><p dir="RTL">- احتباس البول، تكون الجلوكوز في البول</p><p dir="RTL">- ارتفاع مستويات الكرياتينين في الدم (مؤشر لضعف وظائف الكلى)، كما تم الكشف عنها من خلال إجراء فحص لعينة الدم.</p><p dir="RTL"><strong>تأثيرات جانبية أخرى </strong><strong>]</strong><strong>معدل تكرار حدوثها غير معروف (لا يمكن تقدير معدل تكرار حدوثها من البيانات المتاحة)</strong><strong>[</strong></p><p dir="RTL">- الربو</p><p dir="RTL">- تفاعلات تحسسية على سبيل المثال:</p><p dir="RTL">- طفح جلدي</p><p dir="RTL">- احمرار الجلد</p><p dir="RTL">- الشرى (خلايا النحل)</p><p dir="RTL">- الشعور بالحكة</p><p dir="RTL">- تورم الجفون، صعوبة في التنفس</p><p dir="RTL">- الحساسية المفرطة والتفاعلات التأقية. يتم حدوث هذه التفاعلات التحسسية بسرعة ويمكن أن تكون مهددة للحياة. تشمل أعراض الحساسية المفرطة على:</p><p dir="RTL">- فرط الحرارة الخبيث</p><p dir="RTL">- وذمة وعائية (تورم في جلد الوجه، الأطراف، الشفتين، اللسان أو الحلق)</p><p dir="RTL">- صعوبة في التنفس</p><p dir="RTL">- انخفاض ضغط الدم</p><p dir="RTL">- الشرى (خلايا النحل)</p><p dir="RTL">- نوبات تشبه الصرع</p><p dir="RTL">- حركات ارتعاش بصورة مفاجئة</p><p dir="RTL">- توقف القلب</p><p dir="RTL">- تقلصات في الشعب الهوائية</p><p dir="RTL">- صعوبة في التنفس أو صفير</p><p dir="RTL">- كتم النفس</p><p dir="RTL">- ضيق في التنفس</p><p dir="RTL">- قصور في وظائف الكبد أو التهاب الكبد، ويتصف على سبيل المثال بفقدان الشهية، الحمى، غثيان، تقيؤ، الشعور بعدم الراحة في البطن، اليرقان وبول داكن اللون.</p><p dir="RTL">- ارتفاع خطير في درجة حرارة الجسم</p><p dir="RTL">- عدم الراحة في الصدر</p><p dir="RTL">- ارتفاع الضغط داخل الجمجمة</p><p dir="RTL">- عدم انتظام ضربات القلب أو الخفقان</p><p dir="RTL">- التهاب البنكرياس</p><p dir="RTL">- ارتفاع في مستويات البوتاسيوم في الدم كما تم الكشف عنها بواسطة فحص عينة الدم</p><p dir="RTL">- تصلب العضلات</p><p dir="RTL">- التهاب الكلى (قد تشمل الأعراض على حمى، ارتباك أو نعاس، طفح جلدي، انتفاخ، بول أكثر أو أقل من المعتاد وظهور دم في البول)</p><p dir="RTL">- تورم</p><p dir="RTL">في بعض الأحيان لوحظ حدوث صرع (نوبات). يمكن أن تحدث هذه الحالة عند تلقي سيفوفلوران أو أثناء اليوم التالي من الشفاء. غالباً ما تحدث عادةً لدى الأطفال والمراهقين.</p><p dir="RTL">من الممكن أن يحدث تباطؤ في معدل ضربات القلب لدى الأطفال الذين يعانون من متلازمة داون والذين يتلقون سيفوفلوران. قد يعاني الأطفال المصابون بمرض بومبي، وهو مرض يصابون به منذ الولادة من عدم انتظام ضربات القلب أثناء التخدير باستخدام سيفوفلوران.</p><p dir="RTL">قد ترتفع مستويات الفلوريد في الدم بشكل طفيف أثناء التخدير وبعده مباشرة، ولكن لا يعتقد أن هذه المستويات ضارة وسرعان ما تعود إلى وضعها الطبيعي.</p><p dir="RTL">يرجى منك التواصل مع طبيبك المعالج أو الصيدلي الذي تتعامل معه، في حال زيادة حدة أياً من هذه التأثيرات الجانبية، أو لاحظت حدوث أية تأثيرات جانبية لم يتم ذكرها في هذه النشرة.</p><p dir="RTL">يرجى منك إبلاغ طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا لاحظت أية تغيرات في الطريقة التي تشعر بها بعد استعمال سيفوفلوران. حيث أن بعض التأثيرات الجانبية قد تحتاج إلى علاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الإبلاغ عن التأثيرات الجانبية:</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، في حال حدوث أياً من التأثيرات الجانبية بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك&nbsp; الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>&middot;&nbsp; </strong><strong>المملكة </strong><strong>العربية</strong><strong> السعودية:</strong></p><p dir="RTL"><strong>&nbsp;المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL">-&nbsp;&nbsp; <strong>رقم الفاكس: </strong>7662-205-11-966+</p><p dir="RTL">-&nbsp;&nbsp; <strong>مركز الاتصال الموحد:</strong> 19999</p><p dir="RTL">-&nbsp;&nbsp; <strong>البريد الإلكتروني:</strong>&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp; ا<strong>لموقع الإلكتروني:</strong> https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&middot;&nbsp; </strong><strong>دول الخليج العربي الأخرى:</strong></p><p dir="RTL">-&nbsp;&nbsp; الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p dir="RTL">إن الإبلاغ عن التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:54.15pt;margin-top:.65pt;width:21.2pt;
 height:5.75pt;z-index:251667456'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" />يجب عدم استعمال &nbsp;&nbsp;<strong>سوجورن</strong>بعد تاريخ انتهاء الصلاحية المذكور على كلاً من الملصق الداخلي و العبوة. يشير تاريخ الانتهاء إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; يجب عدم حفظه في درجة حرارة أعلى من 30&deg;م، تجنب تجميده. يرجى منك إغلاق الغطاء بشكل محكم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape
 id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:53.1pt;margin-top:.4pt;width:21.2pt;height:5.75pt;
 z-index:251668480'>
 <v:imagedata src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="28" height="8" src="file:///C:/Users/DELL/AppData/Local/Packages/oice_16_974fa576_32c1d314_387a/AC/Temp/msohtmlclip1/01/clip_image002.gif" />يجب عدم استعمال&nbsp;<strong> </strong><strong>سوجورن&nbsp;</strong>إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>يحتوي <strong>&nbsp;سوجورن&nbsp;</strong>على 100% من المادة الفعالة سيفوفلوران. لا توجد أية مواد غير فعالة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر سائل&nbsp;&nbsp;<strong>سوجورن&nbsp;</strong>المتطاير للاستنشاق في عبوات كهرمانية اللون تحتوي على 250 ملليلتر.&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">صُنع بواسطة: <strong>شركة بيرامال للعناية المكثفة.</strong></p><p dir="RTL">3950 دائرة شيلدن، بيت لحم، بنسيلفانيا 18017، الولايات المتحدة الأمريكية.</p><p dir="RTL">8431-822 (888)</p><p dir="RTL">المسوّق: جلفار، الخليج للصناعات الدوائية</p><p dir="RTL">رأس الخيمة، الإمارات العربية المتحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             م 7/4/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sojourn, USP
100%v/v
Liquid for Inhalation, Volatile

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The finished product is comprised only of the active ingredient Sevoflurane.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sojourn is a non-flammable volatile liquid. Sojourn is administered via inhalation of the vaporised liquid.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Induction and maintenance of general anaesthesia in adult and paediatric patients of all ages, including full term neonates (see section 4.2 for age details).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Premedication should be selected according to the need of the individual patient, and at the discretion of the anaesthetist.</p><p><strong>Surgical Anaesthesia:</strong></p><p><strong>Sojourn </strong>should be delivered via a vaporizer specifically calibrated for use with <strong>Sojourn </strong>so that the concentration delivered can be accurately controlled.</p><p>MAC (minimum alveolar concentration) values for <strong>Sojourn</strong> decrease with age and with the addition of nitrous oxide. Dosage should be individualised and titrated to the desired effect according to the patient&#39;s age and clinical status. The table below indicates average MAC values for different age groups.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:516px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1: MAC values for Adults and Paediatric patients according to age</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Age of Patient (years)</strong></p></td><td style="vertical-align:top"><p><strong>Sojourn volatile liquid for inhalation in Oxygen</strong></p></td><td style="vertical-align:top"><p><strong>Sojourn volatile liquid for inhalation in 65% N<sub>2</sub>O/35% O<sub>2</sub></strong></p></td></tr><tr><td style="vertical-align:top"><p>0 &ndash; 1 months*</p></td><td style="vertical-align:top"><p>3.3%</p></td><td rowspan="4" style="vertical-align:top"><p>2.0%**</p></td></tr><tr><td style="vertical-align:top"><p>1 - &lt; 6 months</p></td><td style="vertical-align:top"><p>3.0%</p></td></tr><tr><td style="vertical-align:top"><p>6 months - &lt; 3 years</p></td><td style="vertical-align:top"><p>2.8%</p></td></tr><tr><td style="vertical-align:top"><p>3 &ndash; 12</p></td><td style="vertical-align:top"><p>2.5%</p></td></tr><tr><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>1.4%</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>2.1%</p></td><td style="vertical-align:top"><p>1.1%</p></td></tr><tr><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>1.7%</p></td><td style="vertical-align:top"><p>0.9%</p></td></tr><tr><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>1.4%</p></td><td style="vertical-align:top"><p>0.7%</p></td></tr></tbody></table><p>* Neonates are full term gestational age. MAC in premature infants has not been<br />&nbsp;&nbsp;&nbsp; determined.</p><p>** In 1 &ndash; &lt;3 year old paediatric patients, 60% N<sub>2</sub>O/40% O<sub>2</sub> was used.</p><p><strong>Anaesthesia Induction</strong></p><p>Dosage should be individualised and titrated to the desired effect according to the patient&#39;s age and clinical status. A short acting barbiturate or other intravenous induction agent may be administered followed by inhalation of sevoflurane.</p><p>Induction with sevoflurane may be achieved by inhalation of 0.5-1.0% sevoflurane in oxygen (O<sub>2</sub>) with or without nitrous oxide (N<sub>2</sub>O), increasing by increments of 0.5-1.0% sevoflurane, to a maximum of 8% in adults and children until the required depth of anaesthesia is achieved.</p><p>In adults inspired concentrations of up to 5% sevoflurane usually produce surgical anaesthesia in less than 2 minutes. In children, inspired concentrations of up to 7% sevoflurane usually produce surgical anaesthesia in less than 2 minutes.</p><p><strong>Maintenance of Anaesthesia</strong></p><p>Surgical levels of anaesthesia may be maintained by inhalation of 0.5-3% sevoflurane in O<sub>2</sub> with or without concomitant use of N<sub>2</sub>O.</p><p><strong><u>Emergence:</u></strong></p><p>Emergence times are generally short following sevoflurane anaesthesia. Therefore, patients may require early postoperative pain relief. When all anaesthetic administration has been stopped, the patient&#39;s airways should be ventilated with 100% oxygen until complete awakening</p><p><strong>Elderly people:</strong></p><p>MAC decreases with increasing age. The average concentration of sevoflurane to achieve MAC in an 80 year old is approximately 50% of that required in a 20 year old.</p><p><strong>Paediatric population:</strong></p><p>Refer to Table 1 for MAC values for paediatric patients according to age when used in oxygen with or without concomitant use of nitrous oxide.</p><p><em>Impaired kidney function</em></p><p>Due to the small number of patients with renal impairment (baseline serum creatinine greater than 1.5 mg / dl) studied, the safety of sevoflurane administration in this group has not been fully established. Sevoflurane should therefore be administered with caution in patients with renal impairment.</p><p><strong><u>Method of Administration:</u></strong></p><p>Inhalation use. Sevoflurane has to be administered either via face mask or via endotracheal tube. Sevoflurane should be administered only by persons trained in the administration of general anaesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment and circulatory resuscitation must be immediately available. Sevoflurane should be delivered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled. If the carbon dioxide absorbent may be desiccated, it must be replaced before the use of sevoflurane. (see section 4.4.)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sevoflurane should not be used in patients with known or suspected hypersensitivity to sevoflurane or other halogenated anaesthetics (e.g. history of liver function disorder, fever or leucocytosis of unknown cause after anaesthesia with one of these agents).
Sevoflurane is also contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia.
Sevoflurane is contraindicated in patients in whom general anaesthesia is contraindicated.
Sevoflurane should not be used in patients with a history of unexplained moderate/severe hepatic dysfunction with jaundice, fever, and/or eosinophilia in association with halogenated anaesthetics.
Sevoflurane should not be used in patients with a history of confirmed hepatitis due to a halogenated inhalational anaesthetic or a history of unexplained moderate to severe hepatic dysfunction with jaundice, fever, and eosinophilia after anaesthesia with sevoflurane.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevoflurane may cause respiratory depression, which may be augmented by narcotic premedication or other agents causing respiratory depression. Respiration should be supervised and if necessary, assisted.</p><p>Sevoflurane should be administered only by persons trained in the administration of general anaesthesia.</p><p>Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment and circulatory resuscitation must be immediately available. All patients anaesthetised with sevoflurane should be constantly monitored, including electrocardiogram (ECG), blood pressure (BP), oxygen saturation and end tidal carbon dioxide (CO<sub>2</sub>.)</p><p>The concentration of sevoflurane being delivered from a vaporiser must be known exactly. As volatile anaesthetics differ in their physical properties, only vaporisers specifically calibrated for sevoflurane must be used. The administration of general anaesthesia must be individualised based on the patient&#39;s response. Hypotension and respiratory depression increase as anaesthesia is deepened.</p><p>During the use of halogenated inhalational anaesthetics such as sevoflurane, an AV junctional rhythm may develop in isolated cases, especially when a vagolytic drug such as atropine has been given beforehand.</p><p>Awakening delirium is about 2-3 times more common in young children under six years of age than in adults. Agitation in awakening anaesthesia in young children has been reported more frequently with short-awakening anaesthetics such as sevoflurane compared to some other anaesthetics with longer awakening durations, such as propofol and halothane. Rapid emergence in children may be associated with agitation and lack of co-operation (in about 25% of cases).</p><p>As with other halogenated inhalational anaesthetics, sevoflurane has a dilating effect on the systemic and coronary arterial system. Therefore, sevoflurane should be used with caution in patients with coronary heart disease and it is important to maintain normal haemodynamics to avoid myocardial ischemia in these patients.</p><p><strong>Malignant Hyperthermia</strong></p><p>In susceptible individuals, potent inhalation anaesthetic agents may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia. The clinical syndrome is signalled by hypercapnia, and may include muscle rigidity, tachycardia, tachypnoea, cyanosis, arrhythmias, and/or unstable blood pressure. Some of these nonspecific signs may also appear during light anaesthesia, acute hypoxia, hypercapnia and hypovolaemia.</p><p>In clinical trials, one case of malignant hyperthermia was reported. In addition, there have been post marketing reports of malignant hyperthermia. Some of these reports have been fatal.</p><p>Treatment includes discontinuation of triggering agents (e.g. sevoflurane), administration of intravenous dantrolene sodium (consult prescribing information for intravenous dantrolene sodium for additional information on patient management), and application of supportive therapy. Such therapy includes vigorous efforts to restore body temperature to normal, respiratory and circulatory support as indicated, and management of electrolyte-fluid-acid-base abnormalities. Renal failure may appear later, and urine flow should be monitored and sustained if possible. Use of inhaled anaesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in paediatric patients during the postoperative period.</p><p><strong>Perioperative Hyperkalaemia</strong></p><p>Use of inhaled anaesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in paediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatine kinase levels and, in some cases, changes in urine consistent with myoglobinuria. Despite the similarity in presentation to malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state. Early and aggressive intervention to treat the hyperkalaemia and resistant arrhythmias is recommended, as is subsequent evaluation for latent neuromuscular disease. If a neuromuscular disease is suspected, further evaluation should take place.</p><p>Isolated reports of QT prolongation, very rarely associated with Torsades de Pointes (in exceptional cases, fatal), have been received. Caution should be exercised when administering sevoflurane to susceptible patients.</p><p>Isolated cases of ventricular arrhythmia were reported in paediatric patients with Pompe&#39;s disease.</p><p>Caution should be exercised in administering general anaesthesia, including sevoflurane, to patients with mitochondrial disorders.</p><p><strong>Hepatic</strong></p><p>Very rare cases of mild, moderate and severe post-operative hepatic dysfunction or hepatitis with or without jaundice have been reported from post marketing experiences.</p><p>Clinical judgment should be exercised when sevoflurane is used in patients with underlying hepatic conditions or undertreatment with drugs known to cause hepatic dysfunction. In patients who have experienced hepatic injury, jaundice, unexplained fever or eosinophilia after administration of other inhalation anaesthetics, it is recommended to avoid administration of sevoflurane if anaesthesia with intravenous medicinal products or regional anaesthesia is possible (see section 4.8).</p><p>Patients with repeated exposures to halogenated hydrocarbons, including sevoflurane, within a relatively short interval may have an increased risk of hepatic injury.</p><p><strong>General</strong></p><p>During the maintenance of anaesthesia, increasing the concentration of sevoflurane produces dose-dependent decreases in blood pressure. Excessive decrease in blood pressure may be related to depth of anaesthesia and in such instances may be corrected by decreasing the inspired concentration of sevoflurane. Due to sevoflurane&#39;s insolubility in blood, hemodynamic changes may occur more rapidly than with some other volatile anaesthetics. Particular care must be taken when selecting the dosage for patients who are hypovolaemic, hypotensive, or otherwise hemodynamically compromised, e.g., due to concomitant medications.</p><p>As with all anaesthetics, maintenance of haemodynamic stability is important to avoid myocardial ischaemia in patients with coronary artery disease.</p><p>Caution should be observed when using sevoflurane during obstetric anaesthesia because the relaxant effect on the uterus could increase the risk of uterine bleeding (see section 4.6).</p><p>The recovery from general anaesthesia should be assessed carefully before patients are discharged from the recovery room. Rapid emergence from anaesthesia is generally seen with sevoflurane so early relief of postoperative pain may be required. Although recovery of consciousness following sevoflurane administration generally occurs within minutes, the impact on intellectual function for two or three days following anaesthesia has not been studied. As with other anaesthetics, small changes in moods may persist for several days following administration (see section 4.7).</p><p><strong>Replacement of Desiccated CO<sub>2</sub> Absorbents:</strong></p><p>Rare cases of extreme heat, smoke, and/or spontaneous fire in the anaesthesia machine have been reported during sevoflurane use in conjunction with the use of desiccated CO<sub>2</sub> absorbent, specifically those containing potassium hydroxide (e.g. Baralyme). An unusually delayed rise or unexpected decline of inspired sevoflurane concentration compared to the vaporiser setting may be associated with excessive heating of the CO<sub>2</sub> absorbent canister.</p><p>An exothermic reaction, enhanced sevoflurane degradation, and production of degradation products can occur when theCO<sub>2 </sub>absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO<sub>2</sub> absorbent canisters. Sevoflurane degradants (methanol, formaldehyde, carbon monoxide, and Compounds A, B, C, and D) were observed in the respiratory circuit of an experimental anaesthesia machine using desiccated CO<sub>2</sub> absorbents and maximum sevoflurane concentrations (8%) for extended periods of time (&ge; 2 hours). Concentrations of formaldehyde observed at the anaesthesia respiratory circuit (using sodium hydroxide containing absorbents) were consistent with levels known to cause mild respiratory irritation. The clinical relevance of the degradants observed under this extreme experimental model is unknown.</p><p>If a health care professional suspects that the CO<sub>2</sub> absorbent has become desiccated, it must be replaced before subsequent use of volatile anaesthetics (such as sevoflurane). It must be taken into account that the colour indicator does not always change after desiccation has taken place. Therefore, the lack of significant colour change should not be taken as an assurance of adequate hydration. CO<sub>2</sub> absorbents should be replaced routinely regardless of the state of the colour indicator (see Section 6.6).</p><p><strong>Renal Impairment:</strong></p><p>Although data from controlled clinical studies at low flow rates are limited, findings taken from patient and animal studies suggest there is a potential for renal injury, which is presumed due to Compound A. Therefore, sevoflurane should be used with caution in patients with renal insufficiency. Animal and human studies demonstrate that sevoflurane administered for more than 2 MAC hours and at fresh gas flow rates of &lt;2 L/min may be associated with proteinuria and glycosuria. Also see Section 5.1.</p><p>In some studies in rats, nephrotoxicity was seen in animals exposed to levels of Compound A (pentafluoroisopropenyl fluoromethyl ether (PIFE)) in excess of those usually seen in routine clinical practice. Consider all of the factors leading to Compound A exposure in humans, especially duration of exposure, fresh gas flow rate, and concentration of sevoflurane.</p><p>Inspired sevoflurane concentration and fresh gas flow rate should be adjusted to minimize exposure to Compound A. Sevoflurane exposure should not exceed 2 MAC hours at flow rates of 1 to &lt;2 L/min. Fresh gas flow rates &lt;1 L/min are not recommended.</p><p>The mechanism of this renal toxicity in rats is unknown and its relevance to man has not been established. (See Section5.3, Preclinical Safety Data for further details.)</p><p>Sevoflurane should be administered with caution to patients with impaired renal function (GFR &le; 60 ml/min); renal function should be monitored postoperatively.</p><p><strong>Neurosurgery &amp; Neuromuscular Impairment:</strong></p><p>In patients at risk from elevation of intra-cranial pressure, sevoflurane should be administered cautiously in conjunction with techniques to lower intra-cranial pressure (e.g. hyperventilation).</p><p><strong>Seizures:</strong></p><p>Rare cases of seizures have been reported in association with sevoflurane use.</p><p>Use of sevoflurane has been associated with seizures occurring in children and young adults as well as older adults with and without predisposing risk factors. Clinical judgment is necessary before sevoflurane is used in patients at risk of seizures. In children the depth of anaesthesia should be limited. EEG may permit the optimization of sevoflurane dose and help avoid the development of seizure activity in patients with a predisposition for seizures (see section 4.4-Paediatric population).</p><p><strong>Bradycardia in Down Syndrome</strong></p><p>Episodes of severe bradycardia and cardiac arrest, not related to underlying congenital heart disease, have been reported during anesthesia induction with sevoflurane in pediatric patients with Down syndrome. In most cases, bradycardia improved with decreasing the concentration of sevoflurane, manipulating the airway, or administering an anticholinergic or epinephrine.</p><p>During induction, closely monitor heart rate, and consider incrementally increasing the inspired sevoflurane concentration until a suitable level of anesthesia is achieved. Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population.</p><p><strong>Paediatric population:</strong></p><p>The use of sevoflurane has been associated with seizures. Many have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures (see section 4.4 &ndash; Seizures).</p><p>Dystonic movements in children have been observed (see section 4.8).</p><p><u>Down syndrome</u></p><p>A significantly higher prevalence and degree of bradycardia has been reported in children with Down syndrome during and following sevoflurane induction.</p><p>Experience with repeat exposure to sevoflurane is very limited. However, there were no obvious differences in adverse events between first and subsequent exposures.</p><p>Sevoflurane should be used with caution in patients with Myasthenia Gravis.</p><p>Like other halogenated anaesthetics, sevoflurane may cause cough during induction.</p><p>Sevoflurane could cause QTc prolongation. In clinical practice, this rarely lead to Torsades de Pointes. Sevoflurane should be administered with caution to patients at risk, such as elderly and patients diagnosed with congenital prolongation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevoflurane has been shown to be safe and effective when administered concurrently with a wide variety of agents commonly encountered in surgical situations such as central nervous system agents, autonomic drugs, skeletal muscle relaxants, anti- infective agents including aminoglycosides, hormones and synthetic substitutes, blood derivatives and cardiovascular drugs, including epinephrine.</p><p><strong>Beta-sympathomimetic, and Alpha and Beta-sympathomimetic agents</strong></p><p>Beta-sympathomimetic agents like isoprenaline and alpha- and beta- sympathomimetic agents like adrenaline and noradrenaline should be used with caution during sevoflurane narcosis, due to a potential risk of ventricular arrhythmia. The dosage of adrenaline and noradrenaline utilised for local haemostatic action by subcutaneous or-gingival injections should be limited to, for example, 0.1 mg epinephrine within 10 minutes or 0.3 mg within one hour in adults. Parenteral administration of adrenaline and noradrenaline is not recommended.</p><p><strong>Succinylcholine</strong></p><p>Concomitant use of succinylcholine with inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the post-operative period.</p><p><strong>Amphetamine derivatives</strong></p><p>The use of amphetamines and derivatives as well as of ephedrine and derivatives can cause preoperative hypertensive crisis. It is preferable to interrupt treatments some days before surgery.</p><p><strong>Non-selective MAO inhibitors</strong></p><p>Risk of crisis intraoperative collapse cannot be excluded as this has been observed with other halogenated inhalational anaesthetic agents. It is generally recommended that treatment should be stopped 2 weeks prior to surgery.</p><p><strong>Calcium Antagonists</strong></p><p>Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists, in particular dihydropyridine derivatives.</p><p>Caution should be exercised when calcium antagonists are used concomitantly with inhalation anesthetics due to the risk of additive negative inotropic effect.</p><p><strong>&nbsp;</strong></p><p><strong>Epinephrine/Adrenaline</strong></p><p>Sevoflurane is similar to isoflurane in the sensitisation of the myocardium to the arrhythmogenic effect of exogenously administered adrenaline, the threshold dose of adrenaline producing multiple ventricular arrhythmias has been established at 5 microgram per Kg.</p><p><strong>Indirect-acting Sympathomimetics</strong></p><p>There is a risk of acute hypertensive episode with the concomitant use of sevoflurane and indirect-acting sympathomimetic products (amphetamines, ephedrine).</p><p><strong>Beta blockers</strong></p><p>Sevoflurane may increase the negative inotropic, chronotropic and dromotropic effects of beta blockers (by blocking cardiovascular compensatory mechanisms). Patients should be warned against interruption of beta-blockers and in any case abrupt interruption of the medication is to be avoided. The anaesthetist should be informed of beta-blocker therapy.</p><p><strong>Verapamil</strong></p><p>Impairment of atrioventricular conduction was observed when verapamil and sevoflurane were administered at the same time.</p><p><strong>Inducers of CYP2E1</strong></p><p>Medicinal products and compounds that increase the activity of cytochrome P450 isoenzyme CYP2E1, such as isoniazid and alcohol, may increase the metabolism of sevoflurane and lead to significant increases in plasma fluoride concentrations. Concomitant use of sevoflurane and isoniazid can potentiate the hepatotoxic effects of isoniazid. Due to possible induction of metabolism, isoniazid treatment should be discontinued 1 week before surgery and not restarted until 15 days after surgery.</p><p><strong>St. John&#39;s Wort</strong></p><p>Severe hypotension and delayed emergence from anaesthesia with halogenated inhalational anaesthetics have been reported in patients treated long-term with St. John&#39;s Wort.</p><p><strong>Barbiturates</strong></p><p>Sevoflurane administration is compatible with barbiturates, propofol and other commonly used intravenous anaesthetics. Lower concentrations of sevoflurane may be required following use of an intravenous anaesthetic.</p><p><strong>Benzodiazepines and Opioids</strong></p><p>Benzodiazepines and opioids are expected to decrease the MAC of sevoflurane in the same manner as with other inhalational anaesthetics. Sevoflurane administration is compatible with benzodiazepines and opioids as commonly used in surgical practice.</p><p>Opioids such as alfentanil and sufentanil, when combined with sevoflurane, may lead to a synergistic fall in heart rate, blood pressure and respiratory rate.</p><p><strong>Nitrous Oxide</strong></p><p>As with other halogenated volatile anaesthetics, the MAC of sevoflurane is decreased when administered in combination with nitrous oxide. The MAC equivalent is reduced approximately 50% in adult and approximately 25% in paediatric patients (see section 4.2 &ndash; Maintenance).</p><p><strong>Neuromuscular Blocking Agents</strong></p><p>As with other inhalational anaesthetic agents, sevoflurane affects both the intensity and duration of neuromuscular blockade by non-depolarising muscle relaxants. When used to supplement alfentanil-N<sub>2</sub>O anaesthesia, sevoflurane potentiates neuromuscular block induced with Pancuronium, vecuronium or atracurium. The dosage adjustments for these muscle relaxants when administered with sevoflurane are similar to those required with isoflurane. The effect of sevoflurane on succinylcholine and the duration of depolarising neuromuscular blockade has not been studied.</p><p>Dosage reduction of neuromuscular blocking agents during induction of anaesthesia may result in delayed onset of conditions suitable for endotracheal intubation or inadequate muscle relaxation because potentiation of neuromuscular blocking agents is observed a few minutes after the beginning of sevoflurane administration. The action of non-depolarizing muscle relaxants can be antagonized with neostigmine.</p><p>Among non-depolarising agents, vecuronium, pancuronium and atracurium interactions have been studied. In the absence of specific guidelines: (1) for endotracheal intubation, do not reduce the dose of non-depolarising muscle relaxants; and, (2) during maintenance of anaesthesia, the dose of non-depolarising muscle relaxants is likely to be reduced compared to that during N<sub>2</sub>O /opioid anaesthesia. Administration of supplemental doses of muscle relaxants should be guided by the response to nerve stimulation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>Studies in animals have shown reproductive toxicity (see section 5.3). There are no adequate and well-controlled studies in pregnant women; therefore, sevoflurane should be used during pregnancy only if clearly needed.</p><p><em>Labour and Delivery</em></p><p>In a clinical trial, the safety of sevoflurane was demonstrated for mothers and infants when used for anaesthesia during Caesarean section. The safety of sevoflurane in labour and vaginal delivery has not been demonstrated. Caution should be exercised in obstetric anaesthesia due to the relaxant effect of sevoflurane on the uterus and increase in uterine haemorrhage.</p><p><strong><u>Breastfeeding</u></strong></p><p>It is not known whether sevoflurane or its metabolites are excreted in human milk. Caution should be exercised when sevoflurane is administered to nursing mothers.</p><p><strong><u>Fertility</u></strong></p><p>Reproduction studies in rats and rabbits at doses up to 1 MAC have revealed no evidence of impaired fertility due to sevoflurane.</p><p>Sevoflurane should only be used in pregnancy if clearly indicated.</p><p>The increased risk for uterus bleeding due to a relaxation effect of sevoflurane on the uterus.</p><p>Use during labour and delivery is limited to one small study in Caesarean section.</p><p>Animal studies indicate that sevoflurane is not teratogenic.</p><p>Reproduction studies in rats and rabbits (doses up to 1 MAC) showed no effect on male and female reproductive capability. No sign of foetal toxicity was seen in animal studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other agents, patients should be advised that performance of activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, may be impaired for some time after general anaesthesia (see section 4.4).</p><p>Patients should not be allowed to drive for a suitable period after sevoflurane anaesthesia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>As with all potent inhaled anaesthetics, sevoflurane may cause dose-dependent cardiorespiratory depression. Most adverse reactions are mild to moderate in severity and are transient in duration. Nausea and vomiting are commonly observed in the post-operative period, at a similar incidence to those found with other inhalation anaesthetics. These effects are common sequelae of surgery and general anaesthesia which may be due to the inhalational anaesthetic, other agents administered intra-operatively or post-operatively and to the patient&#39;s response to the surgical procedure. The most commonly reported adverse reactions were as follows:</p><p>In adult patients: hypotension, nausea and vomiting;</p><p>In elderly patients: bradycardia, hypotension &nbsp;and nausea; and</p><p>In paediatric patients: agitation, cough, vomiting and nausea.</p><p><strong>Tabulated summary of adverse reactions</strong></p><p>Adverse event data are derived from controlled clinical trials conducted in the United States and Europe in over 3,200 patients. The type, severity, and frequency of adverse events in sevoflurane patients were comparable to adverse events in patients treated with other inhalation anaesthetics.</p><p>The most frequent adverse events associated with sevoflurane overall were nausea (24%) and vomiting (17%). Agitation occurred frequently in children (23%).</p><p>All Adverse reactions at least possibly relating to sevoflurane from clinical trials and post-marketing experience are presented in the following table by MedDRA System Organ Class, Preferred Term and frequency. The following frequency categories are used: Very common (&gt;1/10); common (&gt;1/100, &lt;1/10); uncommon (&gt;1/1,000, &lt;1/100); rare (&gt;1/10,000, &lt;1/1,000); very rare (&lt;1/10,000), including isolated reports. Post-marketing adverse reactions are reported voluntarily from a population with an unknown rate of exposure. Therefore, it is not possible to estimate the true incidence of adverse events and the frequency is &ldquo;unknown&rdquo;. The type, severity, and frequency of adverse reactions in sevoflurane patients in clinical trials were comparable to adverse reactions in reference-drug patients.</p><p><strong>Adverse Reaction Data Derived From Clinical Trials and Post-marketing Experience</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:534px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Summary of Most Frequent Adverse Drug Reactions in sevoflurane Clinical Trials and Post-marketing Experience</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td rowspan="3" style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Anaphylactic reaction <sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactoid reaction</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity <sup>1</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Leukopenia</p></td></tr><tr><td style="vertical-align:top"><p>Leukocytosis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Agitation</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Confusional state</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Nervous system disorders</p></td><td rowspan="4" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Convulsion<sup> 2, 3</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Dystonia</p></td></tr><tr><td style="vertical-align:top"><p>Increased intracranial pressure</p></td></tr><tr><td rowspan="15" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Tachycardia</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Atrioventricular block complete</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac arrhythmias (including ventricular arrhythmias)</p></td></tr><tr><td style="vertical-align:top"><p>Atrial fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia</p></td></tr><tr><td style="vertical-align:top"><p>Ventricular extrasystoles</p></td></tr><tr><td style="vertical-align:top"><p>Supraventricular extrasystoles</p></td></tr><tr><td style="vertical-align:top"><p>Extrasystoles</p><p>&nbsp;</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>(ventricular, supra-ventricular, bigeminy-linked)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac arrest <sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p>Ventricular fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>Torsades de Pointes</p></td></tr><tr><td style="vertical-align:top"><p>Ventricular tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Electrocardiogram QT prolonged</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Respiratory disorder</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory depression</p></td></tr><tr><td style="vertical-align:top"><p>Laryngospasm</p></td></tr><tr><td style="vertical-align:top"><p>Airway obstruction</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pulmonary oedema</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Apnoea</p><p>Hypoxia</p><p>Asthma</p><p>Bronchospasm</p><p>Dyspnoea <sup>1</sup></p><p>Wheezing <sup>1</sup></p><p>Breath holding</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Salivary hypersecretion</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism And Nutrition Disorders</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Hyperkalaemia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urinary retention</p></td></tr><tr><td style="vertical-align:top"><p>Glycosuria</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Tubulointerstitial nephritis</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td rowspan="4" style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Hepatitis <sup>1, 2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hepatic failure <sup>1, 2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hepatic necrosis <sup>1, 2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Skin and subcutaneous tissue&nbsp; disorders</p></td><td rowspan="5" style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Dermatitis contact <sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rash <sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Swelling face <sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Muscle rigidity</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Chills</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Chest discomfort <sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hyperthermia malignant <sup>1, 2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Oedema</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Investigations</p></td><td rowspan="5" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood glucose abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Liver function test abnormal<sup> 5</sup></p></td></tr><tr><td style="vertical-align:top"><p>White blood cell count abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Blood fluoride increased <sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Serum Creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td></tr><tr><td style="vertical-align:top"><p>Blood lactate dehydrogenase increased</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypothermia</p></td></tr></tbody></table><p>&nbsp;</p><p>1 See section 4.8 &ndash; Description of selected adverse reactions.</p><p>2 See section 4.4.</p><p>3 See section 4.8 &ndash; Paediatric population.</p><p>4 There have been very rare post-marketing reports of cardiac arrest in the setting of sevoflurane use.</p><p>5 Occasional cases of transient changes in hepatic function tests were reported with sevoflurane and reference agents.</p><p><strong>Description of selected adverse reactions</strong></p><p>Transient increases in serum inorganic fluoride levels may occur during and after sevoflurane anaesthesia. Concentrations of inorganic fluoride generally peak within two hours of the end of sevoflurane anaesthesia and return within 48 hours to pre-operative levels. In clinical trials, elevated fluoride concentrations were not associated with impairment of renal function.</p><p>Rare reports of post-operative hepatitis exist. In addition, there have been rare post-marketing reports of hepatic failure and hepatic necrosis associated with the use of potent volatile anaesthetic agents, including sevoflurane. However, the actual incidence and relationship of sevoflurane to these events cannot be established with certainty (see section 4.4).</p><p>Rare reports of hypersensitivity (including contact dermatitis, rash, dyspnoea, wheezing, chest discomfort, swelling face, eyelid oedema, erythema, urticaria, pruritus bronchospasm, anaphylactic or anaphylactoid reactions) have been received, particularly in association with long-term occupational exposure to inhaled anaesthetic agents, including sevoflurane.</p><p>In susceptible individuals, potent inhalation anaesthetic agents may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia (see section 4.4).</p><p><strong>Paediatric population</strong></p><p>The use of sevoflurane has been associated with seizures. Many of these have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Several cases reported no concomitant medications, and at least one case was confirmed by electroencephalography (EEG). Although many cases were single seizures that resolved spontaneously or after treatment, cases of multiple seizures have also been reported. Seizures</p><p>have occurred during, or soon after sevoflurane induction, during emergence, and during post-operative recovery up to a day following anaesthesia. Clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures (see section 4.4).</p><p>&nbsp;</p><p><strong><u>Healthcare professionals are asked to report any suspected adverse reactions via: </u></strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p><strong>The National Pharmacovigilance Centre (NPC):</strong></p><p><strong>&nbsp;&nbsp; - Fax: </strong>+966-11-205-7662</p><p><strong>&nbsp;&nbsp; - SFDA Call Centre: </strong>19999</p><p><strong>&nbsp;&nbsp; - E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>&nbsp;&nbsp; - Website: </strong>https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States:</strong></p><p>&nbsp;&nbsp; - Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdose include respiratory depression and circulatory insufficiency.</p><p>In the event of overdosage, the following action should be taken: Stop drug administration, establish a clear airway and initiate assisted or controlled ventilation with pure oxygen and maintain adequate cardiovascular function.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco-therapeutic group: anaesthetics, general; Halogenated hydrocarbons</p><p>ATC code: N01 AB08</p><p>Changes in the clinical effects of sevoflurane rapidly follow changes in the inspired concentration. Sevoflurane is a halogenated methyl isopropyl ether inhalational anaesthetic which produces a rapid induction and recovery phase. MAC (minimum alveolar concentration) is age specific (see Section 4.2).</p><p>Sevoflurane produces loss of consciousness, reversible abolition of pain and motor activity, diminution of autonomic reflexes, respiratory and cardiovascular depression. These effects are dose-dependent.</p><p>Sevoflurane has a low blood/gas partition coefficient (0.65) leading to a rapid recovery from anaesthesia.</p><p>Cardiovascular Effects</p><p>As with all other inhalation agents, sevoflurane depresses cardiovascular function in a dose related fashion. In one volunteer study, increases in sevoflurane concentration resulted in decrease in mean arterial pressure, but there was no change in heart rate. Sevoflurane did not alter plasma noradrenaline concentrations in this study. Sevoflurane produces a sensitisation of the myocardium to the arrhythmogenic effect of exogenously administered epinephrine. This sensitisation is similar to that produced by isoflurane.</p><p>Nervous System Effects</p><p>In patients with normal intracranial pressure (ICP), sevoflurane had minimal effect on ICP and preserved CO2responsiveness<strong>. </strong>The safety of sevoflurane has not been investigated in patients with a raised ICP. In patients at risk for elevations of ICP, sevoflurane should be administered cautiously in conjunction with ICP-reducing manoeuvres.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The low solubility of sevoflurane in blood should result in alveolar concentrations which rapidly increase upon induction and rapidly decrease upon cessation of the inhaled agent. The FA / FI (wash-in) value after 30 minutes for sevoflurane is0.85. The FA / FAO (wash-out) value after 5 minutes is 0.15.</p><p>In humans &lt;5% of the absorbed sevoflurane is metabolised sevoflurane is defluorinated via cytochrome p450(CYP)2E1in the liver, resulting in the production of hexafluoro isopropanol (HFIP) with release of inorganic fluoride and carbon dioxide (or a one carbon fragment). HFIP is then rapidly conjugated with glucuronic acid and excreted in the urine. The rapid and extensive pulmonary elimination of sevoflurane minimises the quantity available for metabolism.</p><p>The metabolism of sevoflurane may be increased by known inducers of CYP2E1 (e.g. isoniazid and alcohol), but it is not inducible by barbiturates.</p><p>Transient increases in serum inorganic fluoride levels may occur during and after sevoflurane anaesthesia. Generally, concentrations of inorganic fluoride peak within 2 hours of the end of sevoflurane anaesthesia and return within 48 hours to pre-operative levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data on single and repeated dose toxicity of sevoflurane showed no specific organ toxicity.</p><p>Reproductive studies: Studies on fertility performed in rats indicated a decrease in implantation and pregnancy rates after repeated exposure to anaesthetic doses. Developmental toxicity studies performed in rats and rabbits did not reveal any teratogenic effect. In sub-anaesthetic concentrations during the perinatal phase rats showed a prolongation of gestation.</p><p>Extensive in-vitro and in-vivo mutagenicity studies with sevoflurane yielded negative results. Carcinogenicity studies were not performed.</p><p>Effects on circulatory function and oxygen consumption: The results of studies conducted in dogs indicate that sevoflurane does not cause any coronary steal syndrome and does not exacerbate a pre-existing myocardial ischaemia. Animal studies have shown that hepatic and renal circulation are well maintained with sevoflurane.</p><p>Sevoflurane decreases the cerebral metabolic rate for oxygen (CMRO2) in a fashion analogous to that seen with isoflurane. An approximately 50% reduction of CMRO2 is observed at concentrations approaching 2.0 MAC. Animal studies have demonstrated that sevoflurane does not have a significant effect on cerebral blood flow.</p><p>In animals, sevoflurane significantly suppresses electroencephalographic (EEG) activity comparable to equipotent doses of isoflurane. There is no evidence that sevoflurane is associated with epileptiform activity during normocapnia or hypocapnia. In contrast to enflurane, attempts to elicit seizure-like EEG activity during hypocapnia with rhythmic auditory stimuli have been negative.</p><p>Compound A: Compound A is a degradation product of sevoflurane, which is generated in CO2-absorbers. Its concentration increases normally with increasing absorber temperature, sevoflurane concentration and lowering of the fresh gas flow rate.</p><p>Studies performed in rats have shown a dose and duration of exposure dependent, reversible, nephrotoxicity (single cell necrosis of the proximal tubule cells). In the rat evidence for nephrotoxicity could be found at 25-50 ppm following 6 and12 hours exposure. The relevance to humans is unknown.</p><p>Published studies in animals (including primates) at doses resulting in light to moderate anaesthesia demonstrate that the use of anaesthetic agents during the period of rapid brain growth or synaptogenesis results in cell loss in the developing brain that can be associated with prolonged cognitive deficiencies. The clinical significance of these nonclinical findings in not known.</p><p>In clinical studies the highest concentration of Compound A (using soda lime as CO2 absorbents in the circuit) was 15ppm in children and 32 ppm in adults. In systems using barium lime as CO2 absorbents concentrations of up to 61 ppm were found. Although the experience with low-flow anaesthesia is limited, to date there is no evidence of kidney impairment due to Compound A.</p><p>Compound B: Inhalation exposure to Compound B at concentrations up to 2400 ppm (0.24%) for a duration of three hours resulted in no adverse effects on renal parameters or tissue histology in Wistar rats.</p><p>Carcinogenesis</p><p>No carcinogenicity studies have been performed. No mutagenic effect was found in the Ames test and no chromosomal aberrations were induced in cultivated mammalian cells. Reproduction studies in rats and rabbits at doses up to 1 MAC have not provided evidence of impaired fertility or harm to the fetus due to sevoflurane.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sevoflurane is stable when stored under normal room lighting conditions. No discernible degradation of sevoflurane occurs in the presence of strong acids or heat. Sevoflurane is not corrosive to stainless steel, brass, aluminium, nickel-plated brass, chrome-plated brass or copper beryllium alloy.</p><p>Chemical degradation can occur upon exposure of inhaled anaesthetics to CO2 absorbent within the anaesthesia machine. When used as directed with fresh absorbents, degradation of sevoflurane is minimal and degradants are undetectable or non-toxic. Sevoflurane degradation and subsequent degradant formation are enhanced by increasing absorbent temperature, desiccated CO2 absorbent (especially potassium hydroxide-containing, e.g. Baralyme&reg;),increased Sevoflurane concentration and decreased fresh gas flow. Sevoflurane can undergo alkaline degradation by two pathways. The first results from the loss of hydrogen fluoride with the formation of pentafluoroisopropanyl fluoromethyl ether (PIFE or more commonly known as Compound A). The second pathway for degradation of sevoflurane occurs only in the presence of desiccated CO2 absorbents and leads to the dissociation of sevoflurane into hexafluoroisopropanol (HFIP) and formaldehyde. HFIP is inactive, non-genotoxic, rapidly glucuronidated, cleared and has toxicity comparable to sevoflurane. Formaldehyde is present during normal metabolic processes. Upon exposure toa highly desiccated absorbent, formaldehyde can further degrade into methanol and formate. Formate can contribute to the formation of carbon monoxide in the presence of high temperature. Methanol can react with compound A to form them ethoxy addition product Compound B. Compound B can undergo further HF elimination to form Compounds C, D and E. With highly desiccated absorbents, especially those containing potassium hydroxide (e.g. Baralyme&reg;) the formation of formaldehyde, methanol, carbon monoxide, Compound A and perhaps some of its degradants, Compounds B, C and D may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The recommended shelf life is 60 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Do not refrigerate. Keep cap tightly closed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type III, 250 mL amber glass bottles (with or without an external PVC coating) with two</p><p>component screw cap made up of outer black phenolic cover and inner translucent low density polyethylene cone. The pack is provided with an LDPE yellow‐coloured collar.</p><p>OR</p><p>Type III, 250 mL amber glass bottle (without an external PVC coating) with an integrated adaptor, multicomponent closure attached to the bottle with an aluminium crimp ring.</p><p><strong><u>Description of Container Closure System</u></strong></p><p>Sevoflurane is packaged in a 250 mL bottle with either a screw cap or an Integrated adaptor, multi-component closure as detailed in the tables below. The following container closure presentations are used for Sevoflurane manufactured by Piramal Critical Care, Inc.</p><p>Note: The internal company documents refer the term &ldquo;Integrated Closure&rdquo; and &ldquo;Proprietary Closure&rdquo;. This is the same as &ldquo;Integrated adaptor, multi-component closure&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific work exposure limit established for sevoflurane. However, the National Institute for Occupational Safety and Health has recommended an 8- hour time weighted average limit of 2 ppm for halogenated anesthetic agents in general (0.5 ppm when coupled with exposure to N<sub>2</sub>O) (see &ldquo;Undesirable effects&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07. April. 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>